EA199900675A2 - Полиморф моногидрата зополрестата - Google Patents

Полиморф моногидрата зополрестата

Info

Publication number
EA199900675A2
EA199900675A2 EA199900675A EA199900675A EA199900675A2 EA 199900675 A2 EA199900675 A2 EA 199900675A2 EA 199900675 A EA199900675 A EA 199900675A EA 199900675 A EA199900675 A EA 199900675A EA 199900675 A2 EA199900675 A2 EA 199900675A2
Authority
EA
Eurasian Patent Office
Prior art keywords
zopolrestat
relates
diabetic
monopirate
polymorph
Prior art date
Application number
EA199900675A
Other languages
English (en)
Other versions
EA199900675A3 (ru
Inventor
Джон Фрэнсис Ламберт
Тимоти Норрис
Original Assignee
Пфайзер Продактс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пфайзер Продактс Инк. filed Critical Пфайзер Продактс Инк.
Publication of EA199900675A2 publication Critical patent/EA199900675A2/ru
Publication of EA199900675A3 publication Critical patent/EA199900675A3/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)

Abstract

Данное изобретение относится к моногидрату зополрестата и его полиморфам. Данное изобретение относится также к способам получения моногидрата зополрестата, получения его полиморфов и получения безводного зополрестата. Данное изобретение относится также к композициям, содержащим моногидрат зополрестата и к способам применения моногидрата зополрестата и его композиций для лечения диабетических осложнений, таких как диабетические катаракты, диабетическая ретинопатия или диабетическая невропатия, снижения уровней липидов в крови или уровня мочевой кислоты в крови.
EA199900675A 1998-08-21 1999-08-20 Полиморф моногидрата зополрестата EA199900675A3 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9747498P 1998-08-21 1998-08-21

Publications (2)

Publication Number Publication Date
EA199900675A2 true EA199900675A2 (ru) 2000-02-28
EA199900675A3 EA199900675A3 (ru) 2000-06-26

Family

ID=22263562

Family Applications (1)

Application Number Title Priority Date Filing Date
EA199900675A EA199900675A3 (ru) 1998-08-21 1999-08-20 Полиморф моногидрата зополрестата

Country Status (31)

Country Link
US (1) US6159976A (ru)
EP (1) EP0982306A3 (ru)
JP (1) JP2000072769A (ru)
KR (1) KR20000017411A (ru)
CN (1) CN1245804A (ru)
AP (1) AP9901662A0 (ru)
AU (1) AU4453299A (ru)
BG (1) BG103674A (ru)
BR (1) BR9903873A (ru)
CA (1) CA2280590A1 (ru)
EA (1) EA199900675A3 (ru)
EE (1) EE9900385A (ru)
GT (1) GT199900137A (ru)
HR (1) HRP990259A2 (ru)
HU (1) HUP9902783A3 (ru)
ID (1) ID23307A (ru)
IL (1) IL131419A0 (ru)
IS (1) IS5155A (ru)
MA (1) MA26678A1 (ru)
NO (1) NO994027L (ru)
NZ (1) NZ337363A (ru)
OA (1) OA11150A (ru)
PA (1) PA8480601A1 (ru)
PE (1) PE20000993A1 (ru)
PL (1) PL335016A1 (ru)
SG (1) SG83147A1 (ru)
TN (1) TNSN99159A1 (ru)
TR (1) TR199901996A2 (ru)
UY (1) UY25668A1 (ru)
YU (1) YU39899A (ru)
ZA (1) ZA995297B (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105732640B (zh) 2010-07-16 2019-01-08 纽约市哥伦比亚大学理事会 醛糖还原酶抑制剂及其用途
US8916563B2 (en) 2010-07-16 2014-12-23 The Trustees Of Columbia University In The City Of New York Aldose reductase inhibitors and uses thereof
WO2014126885A1 (en) * 2013-02-13 2014-08-21 Mylari Banavara L Water soluble salts of aldose reductase inhibitors for treatment of diabetic complications
MX2018016122A (es) 2016-06-21 2019-08-01 Univ Columbia Inhibidores de aldosa reductasa y metodos de uso.
CN111065392A (zh) 2017-07-28 2020-04-24 应用治疗公司 用于治疗半乳糖血症的组合物和方法
CA3132136A1 (en) 2019-04-01 2020-10-08 Andrew Wasmuth Inhibitors of aldose reductase
EP4125909A1 (en) 2020-03-31 2023-02-08 Applied Therapeutics Inc. Aldose reductase inhibitors for the treatment of acute respiratory distress syndrome, acute lung inflammation/injury, cardiac injury and anti-viral therapy
CA3176768A1 (en) 2020-05-01 2021-11-04 Shoshana SHENDELMAN Aldose reductase inhibitors for treating sorbitol dehydrogenase deficiency

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4748280A (en) * 1985-11-07 1988-05-31 Pfizer Inc. Certain chlorination process for preparing 2-chloro-1,1,1-(C1 -C6)
US4939140A (en) * 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
US4868301A (en) * 1987-06-09 1989-09-19 Pfizer Inc. Processes and intermediates for the preparation of oxophthalazinyl acetic acids having benzothiazole or other heterocyclic side chains
JPH0676391B2 (ja) * 1987-06-09 1994-09-28 フアイザー・インコーポレイテツド ベンゾチアゾール等の複素環側鎖を有するオキソフタラジニル酢酸類の製造方法
US4904782A (en) * 1988-02-29 1990-02-27 Pfizer Inc. Process for the production of phthalazineacetic acid ester derivatives and a novel intermediate
US4954629A (en) * 1989-05-11 1990-09-04 Pfizer Inc. Process and intermediates for the preparation of oxophthalazinyl acetic acids and analogs thereof
WO1992003432A1 (en) * 1990-08-28 1992-03-05 Pfizer Inc. 3-(5-trifluoromethylbenzothiazol-2-ylmethyl)-4-oxo-3h-phythalazin-1-ylacetic acid monohydrate
US5391551A (en) * 1993-05-10 1995-02-21 Pfizer Inc. Method of lowering blood lipid levels
IL120264A0 (en) * 1996-02-29 1997-06-10 Pfizer Method of reducing tissue damage associated with non-cardiac ischemia

Also Published As

Publication number Publication date
PL335016A1 (en) 2000-02-28
OA11150A (en) 2003-04-16
TNSN99159A1 (fr) 2005-11-10
NZ337363A (en) 2001-01-26
EP0982306A2 (en) 2000-03-01
EP0982306A3 (en) 2000-07-05
YU39899A (sh) 2002-12-10
NO994027L (no) 2000-02-22
EE9900385A (et) 2000-04-17
AP9901662A0 (en) 1999-09-30
BR9903873A (pt) 2000-09-19
CA2280590A1 (en) 2000-02-21
IL131419A0 (en) 2001-01-28
ZA995297B (en) 2001-02-19
GT199900137A (es) 2001-02-09
EA199900675A3 (ru) 2000-06-26
US6159976A (en) 2000-12-12
NO994027D0 (no) 1999-08-20
PA8480601A1 (es) 2000-09-29
TR199901996A2 (xx) 2000-03-21
ID23307A (id) 2000-04-05
IS5155A (is) 2000-02-22
PE20000993A1 (es) 2000-10-04
HUP9902783A3 (en) 2001-01-29
JP2000072769A (ja) 2000-03-07
UY25668A1 (es) 2001-08-27
HRP990259A2 (en) 2000-06-30
CN1245804A (zh) 2000-03-01
AU4453299A (en) 2000-03-09
SG83147A1 (en) 2001-09-18
HUP9902783A2 (hu) 2000-12-28
HU9902783D0 (en) 1999-10-28
MA26678A1 (fr) 2004-12-20
KR20000017411A (ko) 2000-03-25
BG103674A (en) 2000-03-31

Similar Documents

Publication Publication Date Title
BR0310106A (pt) Composto, processo para a produção de um composto, composição farmacêutica, uso do composto e método para o tratamento de um sujeito em sofrimento de uma condição ou doença patalógica
WO2004043954A3 (en) Trans-9,10-dehydroepothilone c and d, analogs thereof and methos of making the same
WO2003022852A3 (en) Furo-and thienopyrimidine derivatives as angiogenesis inhibitors
WO2004108139A8 (en) Use of fused heterocyclic compounds as scce inhibitors for the treatment of skin conditions or cancer
ATE239448T1 (de) Verfahren zur herstellung von wässrigen formulierungen für ophthalmische verwendung
TR200401029T4 (tr) Asilfenil-üre türevleri, imalat yöntemleri ve ilaç maddesi olarak kullanımları
ATE238792T1 (de) Verwendung von makroliden zur behandlung von glaukom
EA199900675A2 (ru) Полиморф моногидрата зополрестата
EA200301203A1 (ru) Новые соединения и композиции как ингибиторы катепсина
DE60233664D1 (de) Verfahren zur herstellung von pyridinverbindungen
DK1532131T3 (da) Motilid-forbindelser
DE60202203D1 (de) Neues verfahren zur herstellung von oxabispidinen
EA200501204A1 (ru) Производные 3-(1-[3-(1,3-бензотиазол-6-ил)пропилкарбамоил]циклоалкил)пропановой кислоты в качестве ингибиторов нейтральной эндопептидазы (nep)
DE602004008496D1 (de) Verfahren zur herstellung von (s)-glyceraldehydacetonid
IL166103A0 (en) Pyrrolidine derivatives and their use
EA200501734A1 (ru) Способ получения (4-гидрокси-6-оксотетрагидропиран-2-ил)ацетонитрила и его производных
HK1050141A1 (en) Inhibitor for 20-hete-yielding enzyme
DE69926223D1 (de) Verfahren zur herstellung von zwischenprodukten
ATE497958T1 (de) Verfahren zur herstellung von synthetischen derivaten von dibenzylbutyrolacton-lignanen mit antichagas eigenschaften
WO2002098843A3 (en) Certain salts of discodermolide acid, pharmaceutical compositions containing them and their use in treating tumors
ATE299862T1 (de) Verfahren zur herstellung von ketiminen
DE60108112D1 (de) Verfahren zur herstellung von carbostyril-derivaten
EA200301133A1 (ru) Способ получения дифторбензилэпоксидов и промежуточные соединения
NO20031137L (no) Foreliggende oppfinnelse angår en fremgangsmåte for fremstilling av kiraleforbindelser under betingelsene for en 1,4-Michael-addisjon.Oppfinnelsen angårogså de tilsvarende forbindelser
ECSP993111A (es) Polimorfo de monohidrato de zopolrestat